Official Title
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Brief Title
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Protocol ID
NCT05910710
Lead Sponsor
Samsung Medical Center
Brief Summary
It analyzes the Tumor microenvironment(TME) changes in non pathologic complete
response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and
those who were not administered neoadjuvant pembrolizumab for triple negative breast
cancer.
(Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin,
Cyclophosphamide +- Pembrolizumab regimen)
Study Period
-
Enrollment Count
50 participants
Eligibility Criteria
Inclusion Criteria:
- Triple negative breast cancer
- Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by
Doxorubicin, Cyclophosphamide add Pembrolizumab or not
- Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy
- Sign to informed consent
Exclusion Criteria:
- Patients with difficulty in obtaining sufficient samples
Filters
Triple Negative Breast Cancer
Neoadjuvant Chemotherapy
Pembrolizumab
Tumor Microenvironment
UNKNOWN
ADULT
OLDER_ADULT